STOCK TITAN
  1. Home
  2. Sec-filings
  3. BMEA
  4. [SCHEDULE 13G/A] Biomea Fusion, Inc. SEC Filing

[SCHEDULE 13G/A] Biomea Fusion, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock BMEA logo
Biomea Fusion, Inc.

NASDAQ:BMEA

BMEA Rankings

#4895 Ranked by Market Cap
N/A Ranked by Dividends

BMEA Latest News

Oct 7, 2025
Biomea Fusion Announces Pricing of Public Offering of Securities
Oct 6, 2025
Biomea Fusion Announces Proposed Public Offering of Securities
Oct 6, 2025
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
Oct 1, 2025
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Sep 16, 2025
Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update

BMEA Latest SEC Filings

Oct 7, 2025
[8-K] Biomea Fusion, Inc. Reports Material Event
Oct 7, 2025
[424B5] Biomea Fusion, Inc. Prospectus Supplement (Debt Securities)
Oct 6, 2025
[424B5] Biomea Fusion, Inc. Prospectus Supplement (Debt Securities)
Oct 6, 2025
[8-K] Biomea Fusion, Inc. Reports Material Event
Aug 13, 2025
[SCHEDULE 13G/A] Biomea Fusion, Inc. SEC Filing

BMEA Stock Data

99.97M
53.87M
9.47%
48.39%
13.52%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN CARLOS